Expert opinion: The use of CDK4/6i represents a major milestone in breast cancer treatment. Moreover, transcription-related CDKs play critical roles in tumor development and are promising therapeutic targets for breast cancer. Some relevant clinical studies are underway. More specific and efficient CDKis will undoubtedly be developed and...
Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes - BMC Women's Health
Source : https://bmcwomenshealth.biomedcentral.com/articles/10.1186/s12905-022-01846-3
Background Today, with the progress of medical sciences, increasing the cure probability and survival time is an important goal of cancer treatment. This study compared long-term disease-free survival (DFS) of...
Conclusion: Our results confirm that the most prevalent breast cancer was HR /HER2− tumor type which had the best prognosis. It is also concluded that HR−/HER2 patients had the worst outcomes, with the highest rates of recurrence and metastasis and the lowest overall and disease-free survival rates.
Venous and arterial thrombosis associated with abemaciclib therapy for metastatic breast cancer - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35767226/
In a real-world setting, abemaciclib was associated with a VTE rate approximately two-fold greater than the already elevated rates reported in the MONARCH trials. Patients developing thrombosis on abemaciclib had...
Conclusion: In a real-world setting, abemaciclib was associated with a VTE rate approximately two-fold greater than the already elevated rates reported in the MONARCH trials. Patients developing thrombosis on abemaciclib had a significantly higher risk of death. Given these findings, studies evaluating the role of thromboprophylaxis in patients...
Hormone Replacement Therapy After Breast Cancer: It Is Time - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35594465/
This article reviews the decades of evidence supporting the reproducible benefits of HRT for menopausal symptom control, improved cardiac health, prevention of hip fracture, reduction in the risk and pace...
-
Albert Dekker4yrissue is in details. ER+ or not; time from Dx, stage of disease
Palbociclib plus letrozole induces a complete metabolic response in metastatic breast cancer patient with idiopathic thrombocytopenia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35758116/
Breast cancer is still the leading cause of cancer-related deaths among women aged 20-59 and metastatic breast cancer remains an incurable disease. The therapeutic paradigm of patients with HR-positive HER2-negative...
Conclusion: We here report a case of a 60-year-old woman with idiopathic thrombocytopenia treated with P plus letrozole, who presented a metabolic complete response.
-
Albert Dekker4yrIt was not ITP it was immune thrombocytopenia secondary to cancer